跳至主要内容
临床试验/NL-OMON56288
NL-OMON56288招募中3 期

SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high-intermediate risk endometrial cancer: a proof-of-concept study - SENGA study

niversitair Medisch Centrum Utrecht0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational invasive

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Clinical FIGO 2012 stage I-II high/high-intermediate risk endometrial cancer;
  • - Scheduled for robot-assisted full pelvic and para-aortic staging;
  • - Age >=18 years and able to provide informed consent.

排除标准

  • - Pregnancy or current breastfeeding (in women at a fertile age with a
  • possibility of pregnancy, confirmation by a pregnancy test is current standard
  • - Prior severe allergic reaction to iodine;
  • - Severe renal insufficiency (stage 3 or 4);
  • - Clinical or radiological evidence of metastatic disease.

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验

SENtinel lymph node mapping with... | 临床试验